These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 3304465)
21. Treatment of multiple myeloma by high dose chemotherapy, total body irradiation and autologous blood stem cell autograft. Fermand JP; Lévy Y; Gerota J; Benbunan M; Cosset JM; Castaigne S; Seligmann M; Brouet JC Nouv Rev Fr Hematol (1978); 1989; 31(2):85-7. PubMed ID: 2570400 [TBL] [Abstract][Full Text] [Related]
22. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma. Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951 [TBL] [Abstract][Full Text] [Related]
23. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. Cunningham D; Paz-Ares L; Milan S; Powles R; Nicolson M; Hickish T; Selby P; Treleavan J; Viner C; Malpas J J Clin Oncol; 1994 Apr; 12(4):759-63. PubMed ID: 8151319 [TBL] [Abstract][Full Text] [Related]
24. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Björkstrand B; Ljungman P; Bird JM; Samson D; Gahrton G Bone Marrow Transplant; 1995 Mar; 15(3):367-71. PubMed ID: 7599560 [TBL] [Abstract][Full Text] [Related]
25. Treatment of multiple myeloma. San Miguel JF; Bladé Creixenti J; García-Sanz R Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392 [TBL] [Abstract][Full Text] [Related]
26. Etoposide and ifosfamide for MP (melphalan and prednisolone)- and VAD (vincristine, adriamycin and dexamethasone)-resistant plasma cell myeloma: a case report. Ikeda K; Abe N; Morioka A; Inoo M; Nagai M; Kubota Y; Irino S Jpn J Med; 1990; 29(5):516-8. PubMed ID: 2089176 [TBL] [Abstract][Full Text] [Related]
27. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506 [TBL] [Abstract][Full Text] [Related]
28. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361 [TBL] [Abstract][Full Text] [Related]
29. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521 [TBL] [Abstract][Full Text] [Related]
30. VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma. McElwain TJ; Gore ME; Meldrum M; Viner C; Judson IR; Malpas JS Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():109-12. PubMed ID: 2697419 [TBL] [Abstract][Full Text] [Related]
31. Autologous bone marrow transplantation in multiple myeloma: a single centre experience of 23 patients. Williams CD; McSweeney EN; Mills W; Wells P; Richards JD; Tobias JS; Goldstone AH Leuk Lymphoma; 1994 Oct; 15(3-4):273-9. PubMed ID: 7866275 [TBL] [Abstract][Full Text] [Related]
32. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Segeren CM; Sonneveld P; van der Holt B; Vellenga E; Croockewit AJ; Verhoef GE; Cornelissen JJ; Schaafsma MR; van Oers MH; Wijermans PW; Fibbe WE; Wittebol S; Schouten HC; van Marwijk Kooy M; Biesma DH; Baars JW; Slater R; Steijaert MM; Buijt I; Lokhorst HM; Blood; 2003 Mar; 101(6):2144-51. PubMed ID: 12456509 [TBL] [Abstract][Full Text] [Related]
33. Limited value of myeloablative therapy for late multiple myeloma. Alexanian R; Dimopoulos M; Smith T; Delasalle K; Barlogie B; Champlin R Blood; 1994 Jan; 83(2):512-6. PubMed ID: 7904486 [TBL] [Abstract][Full Text] [Related]
34. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557 [TBL] [Abstract][Full Text] [Related]